Summit Therapeutics (SMMT)
NASDAQ:SMMT
Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$25.15
$0.42(2.31%)
At close: 4:00 PM EST
$25.15
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$13.83 - $30.98
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.69M
Market Cap
$12.51B
Enterprise Value$15.95B
Total Cash (Recent Filing)$598.73M
Total Debt (Recent Filing)$20.04M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Aug 12, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding776,079,960
10 Day Avg. Volume2,951,332
30 Day Avg. Volume2,690,312
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)19.85
Price to Sales (P/S)0.00
P/FCF Ratio-40.41
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-430.99K
Enterprise Value/Ebitda-15.69
Forecast
1Y Price Target
$31.42Price Target Upside24.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$7.75M
Bulls Say, Bears Say
Bulls Say
Clinical Trial Interim ReadoutA positive interim progression-free survival result in HARMONi-3 could unlock accelerated regulatory engagement and create a clearer path toward potential approval in first-line non-small cell lung cancer.
Mechanism Of Action And DifferentiationIvonescimab's PD-1xVEGF bispecific mechanism and cooperative binding may deliver stronger disease control and early survival signals versus PD-1 monotherapy, reinforcing its clinical differentiation.
Supporting External Data And Global TrialsParallel late-stage results from the Chinese partner and multiple SMMT-sponsored trials could provide corroborating evidence that reduces dependence on a single pivotal study and bolsters confidence in efficacy.
Bears Say
Competitive And Payer PressureDelayed biosimilar entry for incumbent therapies combined with entrenched contracting dynamics could impede market access and pricing for a new PD-1xVEGF entrant, raising commercial hurdles.
Regulatory Risk – Overall Survival UncertaintyUncertainty about whether progression-free survival benefits will translate into overall survival remains a central regulatory and valuation risk that could limit upside despite favorable PFS data.
Trial Design And Execution RiskStatistically challenging late-stage trial designs and the potential for binary interim outcomes create execution risk that could trigger sharp negative reactions if predefined thresholds are not met.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $13.83 and its highest was $30.98 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $12.51B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 101 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.029.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 776,079,960 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went up 3.024%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.42 (24.92% Upside)
$31.42 (24.92% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.19%
12-Months-Change
Fundamentals
Return on Equity
-296.82%
Trailing 12-Months
Asset Growth
68.79%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$31.42
▲(24.92% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---